EGFR and colorectal cancer: For example, patients with KRAS mutations are known not to respond well to EGFR (Epidermal Growth Factor Receptor) inhibitors, which are often used in colorectal cancer therapy (Martinelli et al., 2020; Sforza et al., 2016).